Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

BACKGROUND: While in vitro and animal studies have shown reduced cytochrome P450 (CYP) 3A activity due to obesity, clinical studies in (morbidly) obese patients are scarce. As CYP3A activity may influence both clearance and oral bioavailability in a distinct manner, in this study the pharmacokinetic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Brill, Margreke J. E., van Rongen, Anne, Houwink, Aletta P. I., Burggraaf, Jacobus, van Ramshorst, Bert, Wiezer, René J., van Dongen, Eric P. A., Knibbe, Catherijne A. J.
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2014
Assuntos:
Original Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171595/
https://ncbi.nlm.nih.gov/pubmed/25141974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-014-0166-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares